Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Smoot

Showing results (101-110 of 180) with videos related to

Pageof 18
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 3, 2018
Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal AdenocarcinomaMotokazu Sugimoto, Michael B Farnell, David M Nagorney, et al.
International Journal of Surgery (London, England)|March 3, 2018
Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study)John R Bergquist, Harsh N Shah, Elizabeth B Habermann, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 16, 2022
Hepatocellular carcinoma as predominant cancer subgroup accounting for sex differences in post-hepatectomy liver failure, morbidity and mortalityGabriel De la Cruz Ku, Matthew Aizpuru, Hubert Hackl, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 28, 2019
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysisSiddhartha Yadav, Hao Xie, Irbaz Bin-Riaz, et al.
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Cancer Research|December 11, 2012
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinomaJoachim C Mertens, Christian D Fingas, John D Christensen, et al.
Cellular and Molecular Gastroenterology and Hepatology|January 14, 2024
Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in CholangiocarcinomaEmilien J Loeuillard, Binbin Li, Hannah E Stumpf, et al.
Surgery|July 6, 2021
Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspirationJennifer A Yonkus, Roberto Alva-Ruiz, Amro M Abdelrahman, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 11, 2015
Metabolic Syndrome is Associated with Increased Postoperative Morbidity and Hospital Resource Utilization in Patients Undergoing Elective PancreatectomyMay C Tee, Daniel S Ubl, Elizabeth B Habermann, et al.
Pageof 18

Showing results (101-110 of 180) with videos related to

Sort By:
Pageof 18
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 3, 2018
Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal AdenocarcinomaMotokazu Sugimoto, Michael B Farnell, David M Nagorney, et al.
International Journal of Surgery (London, England)|March 3, 2018
Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study)John R Bergquist, Harsh N Shah, Elizabeth B Habermann, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 16, 2022
Hepatocellular carcinoma as predominant cancer subgroup accounting for sex differences in post-hepatectomy liver failure, morbidity and mortalityGabriel De la Cruz Ku, Matthew Aizpuru, Hubert Hackl, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 28, 2019
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysisSiddhartha Yadav, Hao Xie, Irbaz Bin-Riaz, et al.
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Cancer Research|December 11, 2012
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinomaJoachim C Mertens, Christian D Fingas, John D Christensen, et al.
Cellular and Molecular Gastroenterology and Hepatology|January 14, 2024
Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in CholangiocarcinomaEmilien J Loeuillard, Binbin Li, Hannah E Stumpf, et al.
Surgery|July 6, 2021
Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspirationJennifer A Yonkus, Roberto Alva-Ruiz, Amro M Abdelrahman, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 11, 2015
Metabolic Syndrome is Associated with Increased Postoperative Morbidity and Hospital Resource Utilization in Patients Undergoing Elective PancreatectomyMay C Tee, Daniel S Ubl, Elizabeth B Habermann, et al.
Pageof 18